Abstract

Aim. To assess the prevalences of genotypes and alleles polymorphisms of reninangiotensin-aldosterone system, and β2-adrenoreceptors, and to evaluate the results in regard to vasopressor levels in blood serum in essential systemic hypertension (ESH) with the left ventricle hypertrophy (LVH) and with none, in Dagestan Republic population. Material and methods. To the assessment, 98 patients included with the diagnosis “essential systemic hypertension with or none LVH”. Genotypes were assessed, of polymorphism A1166C gene AGTR1 and polymorphism Arg16Gly gene ADRB2. The testing of the polymorphisms was performed with allele-specific polymerase chain reaction. Level of angiotensin (At) II, endothelin (et) 1-21 and aldosterone (AS) in blood serum was measured by the hard-phase IeA. Level of ACe was measured by enzymatic method. Statistics was done with the software statistica (version 6.0) and “Biostat 4.03”. Results. In EAH patients with LVH the prevalence of Arg/Arg polymorphism Arg16Gly gene ADRB2 was lower than in control. In EAH with no LVH there is significant decline of AC genotype prevalences of polymorphism A1166C gene AGTR1 and genotype Arg/Arg polymorphism Arg16Gly gene ADRB2. Level of EТ1-21 and АТ II in the group of EAH with no LVH patients was significantly higher than in controls. Level of AT II in EAH with LVH was significantly higher than none LVH group. Increase of the levels of these mediators of AH was followed by a decline of AS level in the groups of patients comparing to controls. In EAH group with LVH significant increase of et 1-21 was associated with the carriage of As polymorphism A1166C gene AGTR1, and genotypes АА and СС of the same polymorphism were associated with the decrease of levels of EТ1-21. In EAH with no LVH a significant decrease of At II level was found in the carriers of AA and AC genotypes of polymorphism A1166C gene AGTR1. Also, the association was found of all genotypes of polymorphism Arg16Gly gene ADRB2 with the decrease of АТ II. Conclusion. In Dagestan population, in EAH with and with no LVH, most significant are genotypes AA, AC and CC of polymorphism A1166C gene AGTR1, and genotypes Arg/Arg, Arg/Gly, Gly/Gly and alleles Arg and Gly polymorphism Arg16Gly gene ADRB2. Pathogenic significance of the mentioned polymorphisms is emphasized by the presence of polymorphism ET1-12, АТ II, Аs in blood serum.

Highlights

  • Таблица 3 Частоты и относительные риски генотипов и аллелей полиморфизма Arg16Gly гена ADRB2 у больных ЭАГ без ГЛЖ

  • Сопоставление распределения частот генотипов и аллелей полиморфизма Arg16Gly гена ADRB2 показало, что в группе больных с ЭАГ с ГЛЖ определяется, аналогично предыдущему случаю, выраженная тенденция к снижению частоты генотипа Arg/Arg по сравнению с контрольной группой (χ2=3,36; Р=0,06), таблица 2.

  • На этом фоне у носителей генотипа АС полиморфизма A1166C гена AGTR1 и у носителей генотипа Arg/Arg полиморфизма Arg16Gly гена ADRB2 при ЭАГ с ГЛЖ определялось достоверное увеличение сывороточного уровня ЭТ1-21 (Р

Read more

Summary

Introduction

Таблица 3 Частоты и относительные риски генотипов и аллелей полиморфизма Arg16Gly гена ADRB2 у больных ЭАГ без ГЛЖ Сопоставление распределения частот генотипов и аллелей полиморфизма Arg16Gly гена ADRB2 показало, что в группе больных с ЭАГ с ГЛЖ определяется, аналогично предыдущему случаю, выраженная тенденция к снижению частоты генотипа Arg/Arg по сравнению с контрольной группой (χ2=3,36; Р=0,06), таблица 2.

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.